Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Indian variant

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

- PMLiVE

Adobe CEO joins Pfizer board

Shantanu Narayen joins corporate governance and science and technology committees

- PMLiVE

New arrivals join BioHub at AZ’s Alderley Park

Six new biopharma start-ups set up at the UK biocluster

- PMLiVE

AZ moves closer to EU approval for ovarian cancer drug

Olaparib on course to be first PARP inhibitor available for ovarian cancer

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

- PMLiVE

FDA to review AZ’s fish oil drug Epanova

Hypertriglyceridaemia treatment acquired as part of Omthera takeover

- PMLiVE

AZ licenses Merck ovarian cancer drug

Pays $50m upfront for MK-1775

- PMLiVE

AZ sponsors heart attack risk app

GRACE 2.0 app aims to help HCPs decide on the most appropriate treatments

- PMLiVE

Rigel plans job cuts in R&D restructure

Follows failure of fostamatinib disodium in rheumatoid arthritis trial

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

AZ’s olaparib enters phase III for ovarian cancer

Development of the drug had previously been halted in 2011

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links